Transforming growth factor-β1 in Balkan endemic nephropathy

Nephron - Clinical Practice

Volumn 111, Issue 2, 2009, Pages

  Dukanović, Ljubica ^a,e   Ležaić, Višnja ^a   Miljković, Dorde ^b   Momčilović, Miljana ^b   Bukvić, Danica ^d   Marić, Ivko ^d   Miljković, Željka ^c   Marinković, Jelena ^c   Mostarica Stojković, Marija ^c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d Institute for Endemic Nephropathy   (Serbia)

^e NONE   (Serbia)

Author keywords

Balkan endemic nephropathy; Plasma TGF 1; Urine TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISPERSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; URINARY EXCRETION;

ADULT; AGED; BALKAN NEPHROPATHY; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA1;

EID: 58149506538     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000191206     Document Type: Article

References (31)

1. Yamamoto T, Noble NA, Miller DA, Border WA: Sustained expression of TGF-β underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
2. 1 and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001;87:240-248.
3. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;9:1286-1291.
4. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G: TGF-β induces a smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent cultured fibroblasts. J Cell Biol 1993;122:103-111.
5. 1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003;18:1115-1121.
6. 1 in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transpl 2002;17:2145-2152.
7. 1 correlates with long-term renoprotection in insulindependent diabetic patients. Am J Kidney Dis 1999;34:818-823.
8. 1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719.
9. 1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001;12:822-827.
10. 1 in membranous glomerulonephritis. Nephrol Dial Transplant 1997;12:2562-2568.
11. 1 in various types of nephropathy. Pharmacol Res 2004;49:293-298.
12. 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrol Dial Transplant 2007;22:3487-3494.
13. Djukanović L, Velimirović D, Sindjić M: Balkan Nephropathy; in De Broe ME, Porter GA, Bennett WM, Verpoolen GA (eds): Clinical Nephrotoxins. Renal Injury from Drugs and Chemicals. Dordrecht, Kluwer, 1988, pp 426-436.
14. Danilović V: Endemic nephropathy in Yugoslavia; in Strahinjić S, Stefanović V (eds): Endemic (Balkan) Nephropathy. Proc 4th Symp, Niš 1979. Niš, Inst Nephr Haemod, Niš, 1981, pp 1-5.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470.
16. Ferluga D, Hvala A, Vizjak A, Trnačević S, Halilbašić A: Renal function, protein excertion and pathology of Balkan endemic nephropathy. III. Light and electron microscopic studies. Kidney Int 1991;40:57-67.
17. 1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 2005;80:1681-1685.
18. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP: Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2005;20:2215-2225.
19. Djukanović L, Marić I, Marinković J, Ignjatović S, Bukvić D: Evaluation of criteria for the diagnosis of Balkan endemic nephropathy. Ren Fail 2007;29:607-614.
20. Bukvić D, Janković S, Arsenović A, Djukanović L: Prevalence of Balkan endemic nephropathy has not changed since 1971 in the Kolubara region in Serbia. Kidney Blood Press Res 2007;30:117-123.
21. 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 1998;53:639-644.
22. 1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
23. 1 in IgA nephropathy. Am J Kidney Dis 2001;38:1191-1198.
24. 1-microglobulin in children and adolescents with type 1 diabetes. Diabetes Care 2000;23:664-668.
25. Ellis D, Forrest KY, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor-β and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 1998;44:950-956.
26. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE: Urinary transforming growth factor-β excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002;25:1072-1077.
27. Murakami K, Takemura T, Hino S, Yoshioka K: Urinary transforming growth factor-β in patients with glomerular diseases. Pediatr Nephrol 1997;11:334-336.
28. Yamamoto T, Noble NA, Cohen AH, et al: Expression of TGF-β in human glomerular disease. Kidney Int 1996;49:461-469.
29. Misseri R, Rink RC, Meldrum DR, Meldrum KK: Inflammatory mediators and growth factors in obstructive renal injury. J Surg Res 2004;119:149-159.
30. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, Jha S, Pigato J, Lemer ML, Poppas DP, Vaughan ED, Felsen D: Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000;58:2301-2310.
31. Savin M, Bumbaširević V, Djukanović L, Petronić V: The significance of apoptosis for early diagnosis of Balkan nephropathy. Nephrol Dial Transplant 2001;16(suppl 6):30-32.